Jones Soda Q4 Results Reflect Narrower Y/Y Loss & Revenue Surge
JSDA reports 450% y/y Q4 revenue growth and sharply reduced losses, driven by strong demand in club channels and licensed product partnerships.
Zacks·3h ago
More News
The Zacks Analyst Blog Highlights Johnson & Johnson, Caterpillar, Qualcomm, Fossil and Jones Soda
Johnson & Johnson is gaining momentum as innovative medicines and a strengthening MedTech business support growth despite key patent headwinds.
Zacks·3mo ago
Top Analyst Reports for Johnson & Johnson, Caterpillar and Qualcomm
JNJ is leaning on Innovative Medicine growth and MedTech momentum to offset the Stelara patent cliff as it heads into 2026.
Zacks·3mo ago
2 Microcaps Stacking the C-suite
AMNF and JSDA are two microcaps adding industry veterans to the C-suite.
Zacks·3mo ago
Jones Soda's Q3 Revenues Rise as Loss Narrows, Outlook Improves
JSDA posts stronger Q3 results with higher revenues, lower losses and improving margins, while management outlines growth plans across core and new product lines.
Zacks·4mo ago
JSDA Posts Q2 Profit From Cannabis Sale Despite Y/Y Revenue Dip
Jones Soda posts Q2 profit from cannabis sale despite a y/y revenue drop, with product launches and retail expansion aimed at fueling growth.
Zacks·7mo ago
Jones Soda Q1 Loss Narrows Y/Y, Expenses Reduce, Revenues Fall 7.8%